ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.38
0.74%
US Tech 100
20,836.00
1.31%
S&P 500
5,930.85
1.09%
US Dollar vs CAD
1.43226
0.00%
Bitcoin
99,036.99
1.31%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Quince Therapeutics Inc (QNCX) Share Price

Quince Therapeutics Inc

Quince Therapeutics Inc (QNCX)

NASDAQ
1.78
0.02
(1.14%)
Closed December 21 3:00PM
Delayed by 15 minutes
1.85
0.07
(3.93%)
After Hours: 5:42PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.85
Bid
1.65
Ask
1.96
Volume
99,818
1.74 Day's Range 1.8312
0.5116 52 Week Range 2.45
Market Cap
81.403M
Previous Close
1.76
Open
1.7667
Last Trade
70
@
1.81
Last Trade Time
Financial Volume
US$ 176,537
VWAP
1.7686
Average Volume (3m)
599,908
Shares Outstanding
44,001,643
Dividend Yield
-
PE Ratio
-2.73
Earnings Per Share (EPS)
-0.71
Revenue
-
Net Profit
-31.39M

About Quince Therapeutics Inc

Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
quincetx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Quince Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker QNCX. The last closing price for Quince Therapeutics was US$1.76. Over the last year, Quince Therapeutics shares have traded in a share price range of US$ 0.5116 to US$ 2.45.

Quince Therapeutics currently has 44,001,643 shares outstanding. The market capitalization of Quince Therapeutics is US$77.44 million. Quince Therapeutics has a price to earnings ratio (PE ratio) of -2.73.

Ask ADVFN Intelligence (AI)

QNCX Latest News

More News

Form S-3 - Registration statement under Securities Act of 1933

December 18 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 14 2024
Edgar (US Regulatory)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

November 13 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 13 2024
Edgar (US Regulatory)

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage...

November 13 2024
Business Wire

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...

November 12 2024
Business Wire

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...

November 11 2024
Business Wire

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...

October 14 2024
Business Wire

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...

September 03 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

August 21 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2-9.756097560982.052.061.752209071.88406444CS
4-0.36-16.28959276022.212.451.682810011.96968446CS
121.0897143.3250032880.76032.450.695999081.43183185CS
261.16168.1159420290.692.450.51163601461.24642263CS
520.7872.89719626171.072.450.51162268351.20908304CS
156-10.08-84.492875104811.9314.60.51164761542.60102509CS
260-45.76-96.114261709747.61121.980.511645995313.68154864CS

QNCX - Frequently Asked Questions (FAQ)

What is the current Quince Therapeutics share price?
The current share price of Quince Therapeutics is US$ 1.85
How many Quince Therapeutics shares are in issue?
Quince Therapeutics has 44,001,643 shares in issue
What is the market cap of Quince Therapeutics?
The market capitalisation of Quince Therapeutics is USD 77.44M
What is the 1 year trading range for Quince Therapeutics share price?
Quince Therapeutics has traded in the range of US$ 0.5116 to US$ 2.45 during the past year
What is the PE ratio of Quince Therapeutics?
The price to earnings ratio of Quince Therapeutics is -2.73
What is the reporting currency for Quince Therapeutics?
Quince Therapeutics reports financial results in USD
What is the latest annual profit for Quince Therapeutics?
The latest annual profit of Quince Therapeutics is USD -31.39M
What is the registered address of Quince Therapeutics?
The registered address for Quince Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Quince Therapeutics website address?
The website address for Quince Therapeutics is quincetx.com
Which industry sector does Quince Therapeutics operate in?
Quince Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

QNCX Discussion

View Posts
TrendTrade2016 TrendTrade2016 4 weeks ago
QNCX BIO BEAST
👍️0
TrendTrade2016 TrendTrade2016 4 weeks ago
qncx breakout
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
QNCX BREAKING 1.8O KEY
👍️0
glenn1919 glenn1919 1 month ago
QNCX...........................https://stockcharts.com/h-sc/ui?s=QNCX&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
QNCX READY TO GO AGAIN
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
QNCX FAST OUT OF THE GATE
👍️0
Laster Laster 2 months ago
Really neat technology AIDE. Novel way of adding a drug into a patients own red blood cell.
Really amazing if it works.
Watching closely here. I think it ran too fast right now without any news.
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
WEEKLY PUSH
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
QNCX AGAIN OFF THAT DIP
👍️0
glenn1919 glenn1919 2 months ago
QNCX.................https://stockcharts.com/h-sc/ui?s=QNCX&p=W&b=5&g=0&id=p86431144783
👍️0
gail gail 2 months ago
moving back up now.
👍️0
glenn1919 glenn1919 2 months ago
QNCX..........................https://stockcharts.com/h-sc/ui?s=QNCX&p=W&b=5&g=0&id=p86431144783
👍️0
gail gail 2 months ago
in on the dip. hi t/t.
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
QNCX BIO BEAST
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
QNCX ON THE MOVE
👍️0
Viewmont Viewmont 4 months ago
$QNCX Nice! https://finance.yahoo.com/news/quince-therapeutics-announces-lancet-neurology-110000014.html
👍️0
INFINITI INFINITI 4 months ago
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Source
👍️0
Monksdream Monksdream 4 months ago
QNCX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
QNCX
👍️0
Monksdream Monksdream 10 months ago
QNCX under $2
👍️0
AKATITUS AKATITUS 1 year ago
Slow climber
👍️0
Monksdream Monksdream 1 year ago
QNCX under $2
👍️0
AKATITUS AKATITUS 1 year ago
Bought some 1.10s
See what happens
👍️0
knrorrel knrorrel 1 year ago
News https://www.stocktitan.net/news/QNCX/quince-therapeutics-to-acquire-ery-del-sp-a-and-its-phase-3-asset-02yx0yj60e08.html
👍️0
AJ Freely AJ Freely 1 year ago
$QNCX - Up 10% Pre-Market/ Current Price $1.75
To Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
👍️0
AJ Freely AJ Freely 1 year ago
$QNCX- Up 26% Pre-Market/ Current Price $1.24
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics
Increases offer to $1.80 per share + CVR to receive 85% of the future net proceeds of Quince as part of the Lighthouse Pharmaceuticals transaction
👍️0
alchemytrader alchemytrader 2 years ago
Happens. Dirty diluting CEOs
👍️0
Backstabbed Backstabbed 2 years ago
Sorry to hear that
👍️0
alchemytrader alchemytrader 2 years ago
not true. i lost my ass trying to swing PSFE HLBZ FUV. took a terrible loss after finally fiving up. Had i held on i would have lost 90-99% of my money.
👍️0
Backstabbed Backstabbed 2 years ago
all about patience. they all run eventually
👍️0
alchemytrader alchemytrader 2 years ago
congrats
👍️0
Backstabbed Backstabbed 2 years ago
$QNCX - added today!
👍️0
Backstabbed Backstabbed 2 years ago
nice. very low PPS here after it hit a high of $1.75 in PM last week
👍️0
Sirpeter Sirpeter 2 years ago
Hi buddy...added it to watch
👍️0
Backstabbed Backstabbed 2 years ago
$QNCX - News out!!! Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
👍️0
tw0122 tw0122 2 years ago
$1.33 running again
👍️0
saj saj 2 years ago
Mid 1.3's nice pop on news
👍️0
makinezmoney makinezmoney 2 years ago
$QNCX: Decent bounce move here..... now 0.74


2 days now back to back....................... it was receding since Summer last ear and now finally going


On WATCH


GO $QNCX
👍️0
cash4 cash4 2 years ago
https://www.otcmarkets.com/filing/html?id=15980132&guid=AKk-kW7ZRh7-B3h
👍️0

Your Recent History

NASDAQ
QNCX
Quince Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads